Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Gynecologic 1

Conditions

Proteus Syndrome 1Neoplasms 1Lymphoma 1Endometrial Neoplasms 1

Interventions

Cyclophosphamide 1492Cisplatin 1414Paclitaxel 1317Radiotherapy 1261Carboplatin 1250Gemcitabine 1215Docetaxel 1109Bevacizumab 1030Fluorouracil 894Doxorubicin 792Dexamethasone 748Rituximab 719Capecitabine 716Oxaliplatin 700pembrolizumab 680Etoposide 678Irinotecan 634Filgrastim 621Cytarabine 586Leucovorin 579Nivolumab 558Vincristine 515Prednisone 475Cetuximab 465Bortezomib 459Erlotinib Hydrochloride 456Trastuzumab 447Methotrexate 438Lenalidomide 427Pemetrexed 420

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Interventional × Miransertib × Clear all
NCT02594215 2022-06-30

Dose Finding Trial of MK-7075 in Children and Adults With Proteus Syndrome

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
6 enrolled

Proteus Syndrome

NCT01473095 2017-10-23

Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1 Completed
120 enrolled
GynecologicLymphoid

Lymphoma, Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡